The (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 13 (4), 389-396
- https://doi.org/10.2165/00019053-199813040-00002
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Assessing community values in health care: Is the ‘Willingness to pay’ method feasible?Health Care Analysis, 1997
- Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.Journal of Clinical Oncology, 1997
- Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.Journal of Clinical Oncology, 1997
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- Assessment of health producing measures across different sectorsHealth Policy, 1995
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Cost-effectiveness ratios: in a league of their ownHealth Policy, 1994
- Cost effectiveness/utility analyses: Do current decision rules lead us to where we want to be?Journal of Health Economics, 1992
- Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?BMJ, 1991
- Applications of cost-benefit analysis to health careJournal of Health Economics, 1987